OBJECTIVES: Biologics such as etanercept are still considered costly treatment options. Benepali^®, an etanercept biosimilar, was launched in April 2016 in Sweden and its penetration in the 50mg etanercept market varies regionally from 1%-63%. Benepali^®in Dalarna has a penetration of 63% at 2 months, following a recommendation to switch patients to Benepali. The study’s objective was to assess the potential 3-year cost saving for Sweden and the 21 county councils, assuming a penetration comparable to the most penetrated county council, using two price scenarios. METHODS: A budget-impact model was developed to estimate the cost saving potential of introducing Benepali^® in Sweden over a 3-year horizon from payer’s perspective. Current etanercept-treated population in the 21 county councils was estimated through Reveal sales data and projected over 3 years using the trends observed for Enbrel^®